Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.65 |
| ▸ | CTSK | P43235 | 4/20 | 0.65 |
| ▸ | BCL2 | P10415 | 1/20 | 0.59 |
| ▸ | CTSB | P07858 | 2/20 | 0.59 |
| ▸ | CTSL | P07711 | 1/20 | 0.59 |
| ▸ | PPARA | Q07869 | 2/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.57 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7409389 | 1.00 | CTSS (0.65) | CTSSCTSKBCL2CTSBCTSL | |
| SCHEMBL3826349 | 0.95 | CTSS (0.66) | CTSSCTSKBCL2CTSBCTSL | |
| SCHEMBL22404737 | 0.95 | CTSS (0.64) | CTSSCTSKCTSBCTSLPPARA | |
| SCHEMBL3355326 | 0.95 | CTSS (0.64) | CTSSCTSKCTSBCTSLPPARA | |
| SCHEMBL85543 | 0.95 | CTSS (0.64) | CTSSCTSKCTSBCTSLPPARA | |
| SCHEMBL27463259 | 0.94 | CTSS (0.59) | CTSSCTSKBCL2CTSBCTSL | |
| SCHEMBL8027435 | 0.94 | CTSS (0.59) | CTSSCTSKBCL2CTSBCTSL | |
| SCHEMBL7235877 | 0.93 | CTSS (0.63) | CTSSCTSKCTSBCTSLPPARA | |
| SCHEMBL1486267 | 0.93 | CTSS (0.63) | CTSSCTSKCTSBCTSLPPARA | |
| SCHEMBL16163459 | 0.93 | CTSS (0.63) | CTSSCTSKCTSBCTSLPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12286455-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2025-04-29 | — | — | US | disclosed |
| US-11382949-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11382949-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-07-12 | — | — | US | disclosed |
| EP-3922639-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3298027-B1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20200354408-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2020-11-12 | — | — | US | disclosed |
| US-20200354408-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2020-11-12 | — | — | US | disclosed |
| US-10793604-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190307838-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2019-10-10 | — | — | US | disclosed |
| US-20170022253-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL INC. (US) | 2017-01-26 | — | — | US | disclosed |
| WO-2016187534-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL, INC. (US) | 2016-11-24 | — | — | WO | disclosed |
| US-5968980-A | ENDOPEPTIDASE 24.11 INHIBITORS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1999-10-19 | — | — | US | disclosed |
| EP-0660840-B1 | PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES | CIBA GEIGY AG (CH) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996026729-A1 | PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES AS ECE INHIBITORS | CIBA-GEIGY AG (CH) | 1996-09-06 | — | — | WO | disclosed |
| US-5550119-A | ENDOTHELIN-CONVERTING ENZYM INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1996-08-27 | — | — | US | disclosed |
| EP-0660840-A1 | PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES. | CIBA GEIGY AG (CH) | 1995-07-05 | — | — | EP | disclosed |
| WO-1994005677-A1 | PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES | CIBA-GEIGY AG (CH) | 1994-03-17 | — | — | WO | disclosed |
| US-5250522-A | Neutral endopeptidase inhibitors; cardiovascular disorders | CIBA-GEIGY CORPORATION (US) | 1993-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022253-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | CTSS 245/4885CTSK 204/4885BCL2 243/4885 |
| US-11382949-B2 | Anthelmintic depsipeptide compounds | ENPP2, ROCK2, RRP12 | CTSS 548/4885CTSK 1247/4885BCL2 14/4885 |
| US-10793604-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | CTSS 245/4885CTSK 204/4885BCL2 243/4885 |
| US-20190307838-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | ENPP2, ROCK2, RRP12 | CTSS 548/4885CTSK 1247/4885BCL2 14/4885 |
| US-20200354408-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | CTSS 245/4885CTSK 204/4885BCL2 243/4885 |
| US-12286455-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | CTSS 245/4885CTSK 204/4885BCL2 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.